NCT01187212View on ClinicalTrials.gov

Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE

PHASE2CompletedINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

November 30, 2013

Study Completion Date

August 31, 2014

Conditions
Malignant Neoplasm of StomachEffects of Chemotherapy
Interventions
DRUG

Capecitabine/Cisplatin + Sorafenib

Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing

DRUG

Capecitabine/Cisplatin

Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day 1

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Asan Medical Center

OTHER